Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | ILOC: synergism of immunomodulation and tumour ablation in CRC

Thibaud Kössler • 28 Jun 2020
ESMO WCGIC 2020
Colorectal Cancer Gastrointestinal Cancer Antibodies Durvalumab
ILOC

Thibaud Kössler, MD, PhD, of Geneva University Hospital, Geneva, Switzerland, describes the ILOC study (NCT03101475), evaluating the synergism of immunomodulation and tumor ablation in patients with incurable liver metastases from colorectal cancer (CRC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Thibaud Kössler

1:19
PEMREC: neo-adjuvant pembrolizumab and RT in rectal cancer
Thibaud Kössler • 29 Jun 2020

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals